NCT05020782

The BeLimumab Antiphospholipid Syndrome Trial (BLAST)

Open-label, Prospective, Phase II Descriptive Pilot Trial of Belimumab Therapy for Refractory and/or Non-criteria Manifestations of Antiphospholipid Syndrome

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: University of Turin, Italy · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL positivity and clinical features attributable to aPL that are resistant to warfarin and/or heparin.

Conditions

• Antiphospholipid Syndrome

Interventions

Type	Name	Description
DRUG	Belimumab	INTERVENTION DRUG: BELIMUMAB 10 MG/KG

Timeline

• Start date: 2022-06-01
• Primary completion: 2024-10-01
• Completion: 2025-01-01
• First posted: 2021-08-25
• Last updated: 2023-01-13

Locations

1 site across 1 country: Italy